Eli Lilly and Company
Eli Lilly and Company sells prescription medicines for cardiometabolic health, oncology, immunology, and neuroscience to healthcare providers, hospitals, and pharmacies via direct sales and wholesale distribution by developing, manufacturing, and commercializing proprietary drugs with a focus on innovation and clinical differentiation.
LOCKED
Market: NormalKey Catalysts & Risks
The most consequential catalyst is retatrutide, the triple-agonist obesity candidate: management has said it holds the data package for obesity, obstructive sleep apnea and knee osteoarthritis pain and plans to file in the U.S. in the first quarter of 2027, with a regulatory decision plausibly arriving in the following 12 to 24 months. A key swing factor is Lilly's long-running dispute with the FDA over whether retatrutide is a biologic or a drug, because a biologics pathway confers materially longer market exclusivity than a new drug application, and an adverse outcome would be mainly downside to the terminal value of the franchise. Foundayo, the oral GLP-1, is a second catalyst: U.S. type 2 diabetes regulatory action is expected around late 2026 and international launches are expected mainly in 2027, which will test whether an oral format broadens the addressable population enough to offset injectable price pressure. The Medicare GLP-1 Bridge programme, running through the end of 2027, is an ambiguous catalyst because it expands covered access substantially while simultaneously tying pricing to government-negotiated levels and fixed patient copays, so volume gains and price concessions pull in opposite directions. Business development is a further swing factor, with a heavy cadence of acquisitions across neuroscience, immunology, oncology and infectious disease whose value depends on later-stage readouts. Timing precision is limited, and much of the retatrutide and generic-tirzepatide narrative is carried by media and trade reporting rather than by company disclosure.
Two structural issues stand out. First, the company's economics are heavily concentrated in a single incretin franchise, and although U.S. patent protection on tirzepatide extends into the mid-2030s, generic manufacturers have already had abbreviated applications accepted for review and copycat supply is appearing in some markets, so the medium-term setup depends on defending exclusivity and transitioning patients to newer molecules before the cliff. Second, pricing is increasingly a policy variable rather than a commercial one: Lilly's most-favoured-nation agreement with the U.S. government caps cash prices for its GLP-1s, links Medicaid and Medicare access to negotiated price points, and commits to parity pricing on new launches, which structurally lowers realised U.S. prices irrespective of volume growth. Governance entrenchment, with a classified board and a supermajority requirement that shareholders declined to remove, adds a modest further risk to minority influence over how these trade-offs are managed. Together these factors cap the multiple the market is likely to pay and make execution on the next-generation pipeline the main defence of the franchise.
Research refreshed: 2nd of October 2026
KPIs and Peer Benchmarks
| EV | P/E | Net Debt/EBIT | Revenue Growth | |
|---|---|---|---|---|
| AbbVie Inc. (ABBV) | 529B | 74.04 | 3.40 | 8.6% |
| Amgen Inc. (AMGN) | 261B | 24.85 | 3.42 | 9.9% |
| AstraZeneca… (AZN) | 274B | 23.65 | 1.98 | 8.6% |
| Bristol-Mye… (BMY) | 159B | 13.48 | 2.47 | -0.2% |
| Johnson & J… (JNJ) | 646B | 29.60 | 1.09 | 6.0% |
| Merck & Co.… (MRK) | 403B | 114.52 | 4.26 | 1.2% |
| Novo Nordis… (NVO) | 181B | 9.49 | 0.67 | 6.4% |
| Novartis AG (NVS) | 308B | 21.31 | 2.54 | 6.0% |
| Pfizer Inc. (PFE) | 221B | 36.73 | 3.89 | -1.6% |
| Eli Lilly a… (LLY) | 1.12T | 38.24 | 1.16 | 44.7% |
AI Opinion
Fundamentals
Exceptional growth with identifiable commercial drivers: Q2 revenue rose approximately 48%, and Mounjaro/Zepbound generated $14.9bn, contributing $6.3bn of growth. Prescription leadership, expanding reimbursement and manufacturing readiness support continued volume growth. The latest earnings call materially strengthens demand visibility versus older reports, but cardiometabolic concentration and declining realized prices remain central risks.
Peer Comparison
Lilly leads all 10 quantified peers on combined growth and quality, supporting a substantial premium. Nevertheless, $704.71 peer-implied fair value is 38.8% below the current price; the report's description of a discount is incorrect. Historical fundamentals-adjusted fair value of $1359.71 offers approximately 18.1% upside, making valuation supportive but not unequivocally cheap.
Macro Environment
The principal transmission channel is valuation: a 5.24% 10-year Treasury yield raises the hurdle for Lilly's premium multiple despite lower short-term rates. Prescription demand is less directly exposed to discretionary spending, but substantial self-pay Zepbound usage creates affordability sensitivity. The earnings call's Medicare Bridge access expansion is more directly relevant to demand than weak sector breadth; current European macro and FX effects are not established.
Key Metrics
TTM revenue growth 49.6%, operating margin 49.72%, ROIC 31% and FCF margin 25.17% demonstrate exceptional operating quality. Current price implies approximately 32.0x FY2026 non-GAAP EPS guidance midpoint. EV/EBITDA of 25.70x is close to the historical median of 25.44x; historical fair-value upside depends on the model's 25% fundamental adjustment. Dividend yield of approximately 0.58% means returns must predominantly come from appreciation.
Insider Activity
Neutral to slightly bearish, with low predictive value: no trades in the latest 30 days and approximately $15.96m of officer selling in days 30-90, entirely under flagged 10b5-1 plans. No purchases are supplied; recurring Endowment sales and the anomalous transaction row should not materially influence conviction.
Income Statement
Q2 operating income increased 77.4% and operating margin reached 54.2%, demonstrating powerful operating leverage. Raised FY2026 guidance of $85-$87bn revenue and $35.50-$36.50 non-GAAP EPS supports the outlook. However, U.S. prices declined 9% excluding favorable rebate adjustments, those adjustments will not repeat in H2, and acquired IPR&D charges of $3.03 per share materially affected adjusted EPS; these do not fully reconcile the separate $3.21bn other-expense uncertainty.
Cash Flow
TTM operating cash flow of $28.1bn exceeded $26.7bn net income, while provider-defined FCF of $20.1bn validates current earnings power. FCF yield is approximately 1.85%, leaving limited valuation support from cash alone. Historical FCF volatility, FY2025 working-capital absorption of $8.1bn and substantial acquisition and manufacturing investment make sustained conversion a necessary confirmation.
Balance Sheet
Debt of $54.9bn and net debt of approximately $45.9bn limit flexibility despite improving debt-to-assets of 38.6%. Net debt is approximately 1.6x TTM operating cash flow; servicing capacity is supported by strong cash generation. Acquisition spending, rising intangibles and $15.2bn of TTM net debt issuance warrant monitoring rather than assuming expansion is entirely internally funded.